Diabetes treatment depends on the type of diabetes, glucose pattern, age, pregnancy status, complications, other illnesses, medication risks and individual circumstances. The overall objective is to reduce harmful hyperglycaemia while avoiding hypoglycaemia and addressing the broader cardiovascular, renal, neurological and ophthalmological consequences of diabetes. Core management may include nutrition, physical activity, glucose monitoring, medication, education and regular clinical review. Type 1 diabetes requires insulin because the body has insufficient endogenous insulin.
Type 2 diabetes may be managed through lifestyle intervention and one or more glucose-lowering medicines, with insulin used when endogenous insulin production becomes inadequate or other circumstances require it. Gestational diabetes is managed with pregnancy-specific glucose targets and may require diet, activity, metformin or insulin. Treatment is therefore not one standard prescription called “the diabetes treatment”; it is a collection of strategies matched to the underlying physiology.
Type 1 diabetes is treated with insulin replacement for life after established clinical disease. Insulin can be delivered through multiple daily injections or an insulin pump, with basal insulin providing background replacement and rapid-acting insulin covering meals and correcting elevated glucose. People are taught how to match insulin to carbohydrate intake and adjust treatment for exercise, illness and other circumstances. Continuous glucose monitoring can provide frequent glucose measurements and may be integrated with insulin pumps.
Hybrid closed-loop systems can automate part of insulin delivery by using sensor data and algorithms, although users still need to understand carbohydrate intake, device operation and safety procedures. The NHS recommends regular HbA1c reviews, glucose monitoring, education in carbohydrate counting and management of hypoglycaemia and hyperglycaemia. Insulin is indispensable in type 1 diabetes because the fundamental defect is severe insulin deficiency, not simply elevated glucose that can be treated by dietary restriction alone.
Type 2 diabetes treatment often begins with lifestyle measures and is then escalated or combined with medicines according to individual needs. Dietary changes can reduce excessive energy intake, improve nutritional quality and alter the amount and timing of carbohydrate reaching the circulation. Physical activity improves insulin sensitivity and can increase glucose uptake by skeletal muscle. Weight reduction can improve insulin resistance in people for whom it is clinically appropriate.
Metformin is a commonly used medicine and reduces hepatic glucose production while improving insulin sensitivity. Other drug classes are selected according to factors such as cardiovascular disease, chronic kidney disease, weight, risk of hypoglycaemia, gastrointestinal effects, injection burden and cost. Some people eventually require insulin because progressive beta-cell dysfunction reduces their capacity to produce enough insulin. The NHS recognises lifestyle changes, metformin and insulin among type 2 treatment approaches.
Modern type 2 diabetes pharmacotherapy includes several classes with different mechanisms. SGLT2 inhibitors reduce renal glucose reabsorption, increasing urinary glucose excretion and providing additional cardiovascular and renal effects in appropriate patients. GLP-1 receptor agonists increase glucose-dependent insulin secretion, reduce glucagon secretion, slow gastric emptying and can reduce appetite; some are also used in obesity treatment. DPP-4 inhibitors prolong endogenous incretin activity and provide glucose lowering with relatively low hypoglycaemia risk when used without insulin or insulin-secretagogue drugs.
Sulfonylureas stimulate pancreatic insulin secretion and can be effective but can cause hypoglycaemia and weight gain. Thiazolidinediones improve insulin sensitivity but have specific contraindications and adverse effects. Treatment guidelines increasingly select drugs according to overall clinical benefit rather than glucose reduction alone, particularly in people with established cardiovascular or kidney disease.
Gestational diabetes requires treatment that accounts for both maternal and fetal physiology. Initial management generally involves a balanced diet, appropriate activity and self-monitoring of blood glucose. If targets are not achieved after lifestyle measures, medication may be required. The NHS states that metformin or insulin may be used, with insulin particularly appropriate when glucose is very high or metformin is unsuitable or insufficient. Insulin requirements may rise as pregnancy progresses because placental insulin resistance increases.
Pregnancy-specific glucose goals are commonly stricter than ordinary adult diabetes targets; ADA guidance specifies fasting below 5.3 mmol/L, one-hour post-meal below 7.8 mmol/L and two-hour post-meal below 6.7 mmol/L for relevant pregnancy groups. Treatment decisions must account for maternal hypoglycaemia risk and fetal growth, and medication plans generally change after delivery because gestational diabetes usually resolves.
Glucose monitoring is a major component of diabetes treatment, but the appropriate method differs by condition. Finger-prick capillary blood glucose meters provide point-in-time readings, whereas continuous glucose monitors estimate interstitial glucose repeatedly and can show trends, time in range and rapid changes. HbA1c provides a longer-term measure of average glycaemia and is usually checked periodically rather than continuously. People using insulin or medicines capable of causing hypoglycaemia may need more frequent monitoring.
Some people with uncomplicated type 2 diabetes treated with diet or medicines that do not normally cause hypoglycaemia may not need routine self-monitoring, because HbA1c can be sufficient for many management decisions. Treatment targets are individualised, since excessively aggressive glucose lowering can cause hypoglycaemia and may be inappropriate for some people.
Comprehensive diabetes treatment also includes prevention and detection of complications. Regular assessment can include HbA1c, blood pressure, cholesterol, renal function, urine albumin, eye examinations and foot checks. Good glucose control reduces the risk of microvascular complications, while management of blood pressure and lipids addresses major cardiovascular risks. Foot care is particularly important when peripheral neuropathy or vascular disease reduces protective sensation or circulation. Eye screening detects retinal changes before they necessarily cause symptoms.
Kidney assessment can identify diabetic kidney disease at an early stage, allowing treatment to reduce progression risk. Education is itself a treatment component because people often administer medicines, adjust insulin, interpret glucose measurements and respond to illness outside clinical settings. Effective diabetes management is therefore a continuing process rather than a single intervention performed at diagnosis.
Acute safety is an essential part of treatment. Insulin and some glucose-lowering medicines can cause hypoglycaemia, which may produce sweating, shaking, hunger, confusion and, when severe, seizures or unconsciousness. People using insulin need to know how to recognise and treat hypos and how illness can alter insulin requirements.
In type 1 diabetes, insufficient insulin during illness can lead to ketone production and DKA, so sick-day rules commonly include continued insulin, increased glucose and ketone monitoring and urgent clinical assessment when indicated. Very high glucose with severe dehydration or altered consciousness can indicate hyperosmolar hyperglycaemic state, particularly in type 2 diabetes. Treatment therefore balances two opposing acute hazards: excessive glucose and insufficient glucose. The appropriate response to a particular reading depends on the person's treatment, symptoms, ketone status and agreed care plan rather than on the number alone.
